People with severe chronic obstructive pulmonary disease (COPD) across England could soon have fairer access to cutting-edge biological treatments, following new NHS England guidance that aims to end the postcode lottery for these potentially life-changing therapies.
The guidance provides a clear framework for Integrated Care Boards (ICBs) and local NHS bodies to assess and approve funding for biologics—sophisticated drugs that target specific parts of the immune system. These treatments are particularly valuable for COPD patients who suffer frequent flare-ups and show signs of eosinophilic inflammation, a specific immune response that can make their condition worse.
COPD affects around 1.2 million people in the UK, causing persistent breathlessness, cough, and recurring chest infections that can severely impact daily life. Whilst standard treatments such as inhalers and steroids remain the foundation of care, biologics offer hope for those patients who don't respond well to conventional therapies. Clinical trials have shown these targeted treatments can reduce both the frequency and severity of dangerous flare-ups, helping people stay out of hospital and maintain a better quality of life.
Until now, access to these expensive treatments has been inconsistent across different NHS regions, creating unfair disparities in care. The new guidance tackles this head-on by establishing clear criteria and processes for local commissioning, ensuring eligible patients receive the same standard of care regardless of where they live in England.
ICBs will now need to develop robust local policies and establish proper clinical pathways to identify suitable patients for referral. Whilst biologics represent a significant breakthrough for carefully selected patient groups, their substantial cost means decisions must be made thoughtfully within NHS budgets. The guidance should help create a more consistent, evidence-based approach to funding these treatments—balancing genuine patient need with responsible use of public resources.